Home       Corporate       Commodities       Economy/Finance        Investor       eFE       Newsbriefs
Friday, April 20, 2001   
 
 

Ranbaxy in expansion mode; inducts 4 senior executives

Sanjay Sardana

New Delhi, April 19 : RANBAXY Ltd is expanding its presence in the global and domestic over-the-counter (OTC) and nutraceutical product segments and has inducted Atul Malhotra from Hindustan Lever Ltd (HLL) as head (global OTC) and regional director for Middle East.

Ranbaxy president Brian Tempest told The Financial Express that atleast four senior level executives have joined the company over the past two months from various multinationals, including HLL, Colgate Palmolive, Gillete and Johnson & Johnson (J&J), to head various positions. These include vice-president (global HR), director (business finance) and director (marketing).

There has been a lot movement with in the organisation as well, Dr Tempest said. The head of Australia and New Zealand operations has been shifted to head German operations, the head of Thailand operations has been moved to South Africa and there is new head of Vietnam operations. The country manager of Ranbaxy’s Vietnam operations has been made managing director of Ranbaxy UK Limited and Ranbaxy Ireland Limited.
Udai Upendra, earlier with HLL and Colgate Palmolive, has joined as vice- president (global HR). Lalit Ahluwalia has left Gillette to join Ranbaxy as director (business finance) while Sanjeev Dani has been hired from J&J as director (marketing).

“The induction of key people will not only help Ranbaxy revive its human resource strength, but is intended to push over the counter and nutraceutical products in overseas and domestic markets,” Dr Brian said.
The company is aggressively working to increase its range of OTC and nutraceutuical products in the domestic markets. The company’s current portfolio of OTC products includes cough and cold and vitamins and other products like ‘Fenules’ (iron capsules), Revital (ginseng) and garlic pills in the nutraceutical segment.

In the cough and cold segment, Ranbaxy’s ‘Revital’ is generating an annual turnover of over Rs 42 crore and ‘Cherrycough’ of over Rs 10 crore in the domestic market. The company is now working to push these products aggressively in the international markets as well.

Ranbaxy’s long-term strategy involves taking the R&D route for developing new research products in herbal medicine and other products which will bring the big bucks.

Apart from this, the company is also aggressively looking at entering the biotechnology sector as well and plans to introduce a healthcare product in China and foray into ‘branded business’ in the UK. Ranbaxy is planning to launch new drug formulations for ulcers, hypertension, psychiatry, cancer and immunosuppressant.

 

 
 
  Search

  

  Other Publications
    Indian Express
Expressindia
Express Computer
Screen
     
    Other Links
    FE Archives
About Us
Advertise with Us
 
Feedback
     
 
   
 
 
 
 
 
 
© 2001: Indian Express Newspapers (Bombay) Ltd. All rights reserved throughout the world.